PERSPECTA

News from every angle

← Back to headlines

Johnson & Johnson Acquires Option for Sail in vivo CAR-T Therapies

Johnson & Johnson has secured a $2.58 billion option to acquire Sail's in vivo CAR-T therapies. This strategic move aims to bolster Johnson & Johnson's presence in the rapidly evolving field of cell-based cancer treatments.

29 Jul, 21:49 — 29 Jul, 21:49
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed5d ago

Johnson & Johnson gets $2.58B option to acquire Sail in vivo CAR-T therapies push

Read full article →

Related Stories

Irish Households Face Record Electricity Bill Arrears

19m ago

Athene Holding Reports Q2 GAAP EPS of $2.18 and $11.15B Revenue

19m ago

Duke Energy Targets $5B-$10B Capital Upside, Reaffirms EPS Growth Through 2030

21m ago

Wealthiest Americans Drive Majority of New Car Sales in the U.S.

23m ago